GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

KKRX:011000
2,670.00
KRW
0.00
(0.00%)
-2,783.52EPS
48.42BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,814.78
22,468.93
4,256.27
4,688.29
3,950.83
4,242.92
5,657.36
2,837.65
2,606.35
3,141.46
2,584.8
2,248.3
1,397.77
703.35
Basic EPS, GAAP
-1,544.38
-5,923.28
212.14
-2,331.18
-3,450.38
-1,472.06
-1,045.09
-1,275.04
-1,070
-2,460
-5,000
-3,055
-3,145
-2,783.52
Free Cash Flow per Basic Share
-474.94
-4,469.92
-201.92
-2,169.84
-647.43
-1,350
-587.06
-2,207.47
-5,883.88
-4,482.87
-1,761.43
-1,222.64
-1,006.87
-757.27
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4,726.75
5,370.49
5,907.24
5,349.01
4,517.5
3,635.99
3,247.17
7,098.58
13,362.75
11,701.46
7,122.6
5,361.75
2,400.11
1,968.01
Tangible Book Value per Share
3,551.38
4,618.23
5,258.07
4,723.39
4,024.75
3,571.21
3,169.05
7,049.36
13,321.13
11,665.1
7,097.95
5,349.85
2,387.88
1,955.93
Basic Weighted Avg Shares
5
1
7
7
7
8
7
15
15
16
16
16
16
18
Sales/Revenue/Turnover
20,657
24,625
28,365
31,371
27,171
34,293
41,241
41,503
38,700
48,718
40,203
35,720
23,045
12,365
Operating Margin (%)
-30.55
-26.1
-12.79
-44.61
-91.5
-32.83
-19.9
-44.48
-70.86
-82.27
-120.31
-134.93
-211.64
-322.99
Depreciation Expense
1,894
1,636
1,124
1,133
1,104
1,294
3,420
4,021
4,650
5,424
12,776
17,961
18,196
17,116
Net Income, GAAP
-8,363
-6,492
1,414
-15,599
-23,730
-11,898
-7,619
-18,648
-15,888
-38,150
-77,768
-48,537
-51,851
-48,936
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-40.48
-26.36
4.98
-49.72
-87.33
-34.69
-18.47
-44.93
-41.05
-78.31
-193.44
-135.88
-225
-395.75
Working Capital
13,090
25,164
28,591
24,233
26,085
19,371
13,943
72,055
99,875
39,227
11,705
-13,870
-34,369
-38,040
LT Debt
- -
- -
- -
- -
- -
- -
2,013
794
7,103
5,509
12,358
20,853
22,284
24,381
Total Equity
23,711
34,731
39,439
35,852
36,540
29,410
24,060
98,509
206,507
181,471
111,489
85,605
40,898
35,689
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-33.15
-22.22
3.81
-41.44
-65.56
-36.08
-28.5
-30.43
-10.42
-19.67
-53.09
-49.25
-81.98
-99.68

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10,674
10,649
10,668
LT Borrowings
20,018
21,113
21,505
LT Finance Leases
2,266
2,390
2,877
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
18
18
Market Capitalization
166,908
83,057
48,420

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
19,437
24,670
23,567
Cash, Cash Equivalents & STI
1,735
5,724
5,873
Accounts Receivable, Net
1,742
1,978
2,036
Inventories
13,422
13,121
12,024
Total Current Liabilities
53,806
53,922
61,607
Payables & Accruals
- -
- -
- -
ST Debt
10,674
10,649
10,668
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.81%
-3.3%
-52.22%
Free Cash Flow
169.43%
9.19%
-14.54%
Net Income, GAAP
-89.39%
39.68%
6.83%
Sales/Revenue/Turnover
-0.07%
-9%
-35.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,032
9,290
8,893
10,505
35,720
2025
8,504
6,813
5,076
2,652
23,045
2026
2,581
2,056
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-605
-195
-1,275
-980.04
-3,055
2025
-555
-935
-675.79
-946.95
-3,145
2026
-131.05
-1,044.9
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Young-Keun Park
Full Time Employees
52
Sector
Health technology
Industry
Biotechnology
Address
The Pinnacle Gangnam Seoul SL South Korea 06060
IPO Date
Nov 16, 1987
Website
genels.com
Business
GeneOne Life Science, Inc. (011000.KS) operates as a biopharmaceutical company focused on the research, development, and contract manufacturing of nucleic acid-based biomedicines, including DNA and mRNA vaccines, gene therapies, plasmid-encoded monoclonal antibodies, recombinant proteins, and small molecule immunotherapeutics; its pipeline features GLS-1027 in Phase I for nephropathy and inflammatory diseases, GLS-1200 in Phase II for rhinosinusitis and COVID-19, GLS-7000 for breast cancer, GLS-7100 for hemophilia A, GLS-8000 for chronic hepatitis B prevention, and GLS-8100 for rheumatoid arthritis, alongside cGMP production of DNA plasmids and mRNA through subsidiary VGXI, Inc. in The Woodlands, Texas. The company targets emerging infectious diseases such as Zika, Lassa fever, Ebola, HIV, MERS, and COVID-19, as well as cancers including HPV-related, glioblastoma multiforme, and prostate cancer, serving global academic and commercial partners in the United States, Korea, Canada, Europe, and resource-challenged regions. Founded in 1976 and headquartered at Parc.1 NH Finance Tower, 20th Floor, Seoul, South Korea, with financial and R&D operations in Seoul and global clinical development in Blue Bell, Pennsylvania, USA, GeneOne Life Science recently expects to receive KRW 5 billion in funding from Shared Growth Fund No. 1 via series 6 unregistered unsecured private convertible bonds issued on October 29, 2025, with payment on November 4, 2025; announced a KRW 10 billion stock sale in September 2025; and received KRW 3.6 billion in funding in March 2024, reflecting ongoing capital raises to support pipeline advancement and manufacturing expansion.